This observational study, called The HOPE Study, is looking to understand more about people with hepatitis B and C infections. You could be eligible if you are at least 18 years old and have hepatitis B, hepatitis C, or a history of either, even if cleared or successfully treated. Healthy volunteers are also welcome. The study involves collecting samples and evaluating how these diseases progress over time, up to 10 years. A sub-study for hepatitis B treatment involves taking tenofovir alafenamide (25 mg tablet, once daily) for two years. Success for this study will be measured by changes in liver stiffness (how stiff your liver is) over two years in participants with chronic hepatitis B. The current recruitment status is unclear.

Study design

This is an observational study with a planned enrollment of 550 participants. It is designed to collect samples and evaluate disease progression over time.

What's involved

You would be seen annually for up to 10 years, with optional additional visits, and provide samples for research. If you are in the hepatitis B treatment sub-study, you would take tenofovir alafenamide daily for two years, have blood draws, and potentially liver transient elastography (FibroScan) and liver biopsies.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 10 years. The primary endpoint for the hepatitis B sub-study is measured at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.